Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

  • Author(s): Karachaliou, Niki
  • Chaib, Imane
  • Cardona, Andres Felipe
  • Berenguer, Jordi
  • Bracht, Jillian Wilhelmina Paulina
  • Yang, Jie
  • Cai, Xueting
  • Wang, Zhigang
  • Hu, Chunping
  • Drozdowskyj, Ana
  • Servat, Carles Codony
  • Servat, Jordi Codony
  • Ito, Masaoki
  • Attili, Ilaria
  • Aldeguer, Erika
  • Capitan, Ana Gimenez
  • Rodriguez, July
  • Rojas, Leonardo
  • Viteri, Santiago
  • Molina-Vila, Miguel Angel
  • Ou, Sai-Hong Ignatius
  • Okada, Morihito
  • Mok, Tony S
  • Bivona, Trever G
  • Ono, Mayumi
  • Cui, Jean
  • Ramón Y Cajal, Santiago
  • Frias, Alex
  • Cao, Peng
  • Rosell, Rafael
  • et al.
Abstract

Epidermal growth factor receptor (EGFR)-mutation-positive non-smallcell lung cancer (NSCLC) is incurable, despite high rates of response to EGFR tyrosine kinase inhibitors (TKIs). We investigated receptor tyrosine kinases (RTKs), Src family kinases and focal adhesion kinase (FAK) as genetic modifiers of innate resistance in EGFR-mutation-positive NSCLC. We performed gene expression analysis in two cohorts (Cohort 1 and Cohort 2) of EGFR-mutation-positive NSCLC patients treated with EGFR TKI. We evaluated the efficacy of gefitinib or osimertinib with the Src/FAK/Janus kinase 2 (JAK2) inhibitor, TPX0005 in vitro and in vivo. In Cohort 1, CUB domain-containing protein-1 (CDCP1) was an independent negative prognostic factor for progression-free survival (hazard ratio of 1.79, p=0.0407) and overall survival (hazard ratio of 2.23, p=0.0192). A two-gene model based on AXL and CDCP1 expression was strongly associated with the clinical outcome to EGFR TKIs, in both cohorts of patients. Our preclinical experiments revealed that several RTKs and non-RTKs, were up-regulated at baseline or after treatment with gefitinib or osimertinib. TPX-0005 plus EGFR TKI suppressed expression and activation of RTKs and downstream signaling intermediates. Co-expression of CDCP1 and AXL is often observed in EGFR-mutation-positive tumors, limiting the efficacy of EGFR TKIs. Co-treatment with EGFR TKI and TPX-0005 warrants testing.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View